cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2023-3416cardiovascular-3416Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEW ARTICLESПатогенетические особенности сердечно-сосудистой патологии у пациентов с остеоартритомPathogenetic features of cardiovascular pathology in patients with osteoarthritishttps://orcid.org/0000-0002-5188-7997АнкудиновА. С.AnkudinovA. S.

Анкудинов Андрей Сергеевич — кандидат медицинских наук, доцент кафедры симуляционных технологий и экстренной медицинской помощи.

Иркутск

Irkutsk

andruhin-box@yandex.ruhttps://orcid.org/0000-0002-2708-3972КалягинА. Н.KalyaginA. N.

Доктор медицинских наук, профессор, заведующий кафедрой пропедевтики.

Иркутск

Irkutsk

andruhin.box@ya.ruИркутский государственный медицинский университет Минздрава РоссииIrkutsk State Medical University20231004202322334163416Copyright © Анкудинов А.С., Калягин А.Н., 20232023Анкудинов А.С., Калягин А.Н.Ankudinov A.S., Kalyagin A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/3416

Сердечно-сосудистая патология занимает ведущее место среди всех причин смерти, стойкой нетрудоспособности и инвалидизации населения. В последние годы отмечается увеличение числа случаев сердечно-сосудистой коморбидности, что приводит к значительному ухудшению качества жизни пациентов, трудностям в подборе терапии и ухудшению прогноза. Актуальным и активно обсуждаемым направлением в данной области является кардиоревматология. Одной из наиболее распространенных ревматических патологий является остеоартрит. Исследователи выделяют ряд негативных факторов, отягощающих течение сердечно-сосудистой патологии при наличии остеоартрита: регулярный прием нестероидных противовоспалительных препаратов, хронический болевой синдром, уменьшение подвижности. В обзоре приводятся современные данные, касающиеся обсуждаемой проблемы, в частности современное понимание патогенетических взаимосвязей. Освещаются вопросы безопасности нестероидных противовоспалительных препаратов у пациентов с сердечно-сосудистой патологией. Описываются возможности применения у данной группы пациентов современных иммунологических цитокинов на примере галектина-3 в качестве маркера прогноза.

Cardiovascular pathology occupies a leading place among all causes of death and permanent disability of the population. In recent years, there has been an increase in the number of cardiovascular comorbidity cases, which leads to a significant deterioration in the quality of life, difficulties in the selection of therapy and a worse prognosis. Cardiorheumatology is an actual and actively discussed direction in this area. One of the most common rheumatic pathologies is osteoarthritis. Researchers identify a number of factors aggravating the course of cardiovascular pathology in the presence of osteoarthritis: regular intake of non-steroidal antiinflammatory drugs, chronic pain syndrome, decreased mobility. The review provides current data on the problem under discussion, in particular, the current understanding of pathogenetic relationships. The issues of safety of non-steroidal anti-inflammatory drugs in cardiovascular patients are highlighted. The potential of using modern immunological cytokines in this group of patients are described using the example of galectin-3 as a marker of prognosis.

артериальная гипертонияишемическая болезнь сердцахроническая сердечная недостаточностьостеоартритнестероидные противовоспалительные препаратыкоморбидностьhypertensioncoronary artery diseaseheart failureosteoarthritisnon-steroidal anti-inflammatory drugscomorbidityReferencesLeong DP, Joseph PG, Kee Mc, et al. Reducing the global burden of cardiovascular disease, part 2: prevention and treatment of cardiovascular disease. Circ Res. 2017;121(6):695-710. doi:10.1161/CIRCRESAHA.117.311849.Leong DP, Joseph PG, Kee Mc, et al. Reducing the global burden of cardiovascular disease, part 2: prevention and treatment of cardiovascular disease. Circ Res. 2017;121(6):695-710. doi:10.1161/CIRCRESAHA.117.311849.Kumar A, Avishay DM, Jones CR, et al. Sudden cardiac death: epidemiology, pathogenesis and management. Rev Cardiovasc Med. 2021; 22(1):147-58. doi:10.31083/j.rcm.2021.01.207.Kumar A, Avishay DM, Jones CR, et al. Sudden cardiac death: epidemiology, pathogenesis and management. Rev Cardiovasc Med. 2021; 22(1):147-58. doi:10.31083/j.rcm.2021.01.207.Miao Q, Zhang YL, Miao QF, et al. Sudden Death from Ischemic Heart Disease While Driving: Cardiac Pathology, Clinical Characteristics, and Countermeasures. Med Sci Monit. 2021;27:e929212. doi:10.12659/MSM.929212.Miao Q, Zhang YL, Miao QF, et al. Sudden Death from Ischemic Heart Disease While Driving: Cardiac Pathology, Clinical Characteristics, and Countermeasures. Med Sci Monit. 2021;27:e929212. doi:10.12659/MSM.929212.Бойцов С. А., Баланова Ю. А., Шальнова С. А. и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014;13(4):4-14. doi:10.15829/1728-8800-2014-4-4-14.Boitsov SA, Balanova YuA, Shalnova SA, et al. Arterial hypertension among people aged 25-64: prevalence, awareness, treatment and control. Based on the materials of the ESSAY study. Cardiovascular Therapy and Prevention. 2014;13(4):4-14. (In Russ.) doi:10.15829/1728-8800-2014-4-4-14.Albasri A. A comparison of blood pressure in community pharmacies with ambulatory, home and general practitioner office readings: systematic review and meta-analysis. J Hypertens. 2017;35(10):1919-26.Albasri A. A comparison of blood pressure in community pharmacies with ambulatory, home and general practitioner office readings: systematic review and meta-analysis. J Hypertens. 2017;35(10):1919-26.Khan MA, Hashim MJ, Mustafa H. Global epidemiology of ischemic heart disease: results from the global burden of disease study. Cureus. 2020;12(7):e9349. doi:10.7759/cureus.9349.Khan MA, Hashim MJ, Mustafa H. Global epidemiology of ischemic heart disease: results from the global burden of disease study. Cureus. 2020;12(7):e9349. doi:10.7759/cureus.9349.Фомин И. В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем, и что должны делать. Российский кардиологический журнал. 2016;(8):7-13. doi:10.15829/1560-4071-2016-8-7-13.Fomin IV. Chronic CHF in the Russian Federation: what we know today and what we should do. Russian Journal of Cardiology. 2016;(8):7-13. (In Russ.) doi:10.15829/1560-4071-2016-8-7-13.Branco JC, Rodrigues AM, Gouveia N, et al. Prevalence of rheumatic and musculoskeletal diseases and their impact on health related quality of life, physical function and mental health in Portugal: results from EpiReumaPt — a national health survey. RMD Open. 2016;2(1):e000166. doi:10.1136/rmdopen-2015-000166.Branco JC, Rodrigues AM, Gouveia N, et al. Prevalence of rheumatic and musculoskeletal diseases and their impact on health related quality of life, physical function and mental health in Portugal: results from EpiReumaPt — a national health survey. RMD Open. 2016;2(1):e000166. doi:10.1136/rmdopen-2015-000166.Prior JA, Jordan KP, Kadam UT. Associations between cardiovascular disease severity, osteoarthritis co-morbidity and physical health: a population-based study. Rheumatology (Oxford). 2014;53(10):1794-802. doi:10.1093/rheumatology/keu175.Prior JA, Jordan KP, Kadam UT. Associations between cardiovascular disease severity, osteoarthritis co-morbidity and physical health: a population-based study. Rheumatology (Oxford). 2014;53(10):1794-802. doi:10.1093/rheumatology/keu175.Anyfanti P, Gkaliagkousi E, Triantafyllou A, et al. Hypertension in rheumatic diseases: prevalence, awareness, treatment, and control rates according to current hypertension guidelines. Hum Hypertens. 2021;35(5):419-27. doi:10.1038/s41371-020-0348-y.Anyfanti P, Gkaliagkousi E, Triantafyllou A, et al. Hypertension in rheumatic diseases: prevalence, awareness, treatment, and control rates according to current hypertension guidelines. Hum Hypertens. 2021;35(5):419-27. doi:10.1038/s41371-020-0348-y.Wallace IJ, Worthington S, Felson DT, et al. Knee osteoarthritis has doubled in prevalence since the mid-20th century. PNAS. 2017;114(35):9332-6. doi:10.1073/pnas.1703856114.Wallace IJ, Worthington S, Felson DT, et al. Knee osteoarthritis has doubled in prevalence since the mid-20th century. PNAS. 2017;114(35):9332-6. doi:10.1073/pnas.1703856114.Кабалык М. А., Невзорова В. А. Кардиоваскулярные заболевания и остеоартрит: общие механизмы развития, перспективы совместной профилактики и терапии. Кардиоваскулярная терапия и профилактика. 2021;20(1):2660. doi:10.15829/1728-8800-2021-2660.Kabalyk MA, Nevzorova VA. Cardiovascular diseases and osteoarthritis: common mechanisms of development, prospects for joint prevention and therapy. Cardiovascular Therapy and Prevention. 2021;20(1):2660. (In Russ.)Pengpid S, Peltzer K. Multimorbidity in chronic conditions: public primary care patients in four greater Mekong countries. Int J Environ Res Public Health. 2017;14:1019-25. doi:10.3390/ijerph14091019.Pengpid S, Peltzer K. Multimorbidity in chronic conditions: public primary care patients in four greater Mekong countries. Int J Environ Res Public Health. 2017;14:1019-25. doi:10.3390/ijerph14091019.Пасеишвили Л. М. Остеоартроз и артериальная гипертензия: механизмы реализации сочетанного течения. Медицина. 2012;21:71-5.Paseishvili LM. Osteoarthritis and arterial hypertension: mechanisms of realization of the combined course. Medicine. 2012;21:71-5. (In Russ.)Ching K, Houard X, Berenbaum F, et al. Hypertension meets osteoarthritis — revisiting the vascular aetiology hypothesis. Nat Rev Rheumatol. 2021;17(9):533-49. doi:10.1038/s41584-021-00650-x.Ching K, Houard X, Berenbaum F, et al. Hypertension meets osteoarthritis — revisiting the vascular aetiology hypothesis. Nat Rev Rheumatol. 2021;17(9):533-49. doi:10.1038/s41584-021-00650-x.Полищук Л. С. Особенности ведения пациентов с сочетанной патологией — остеоартрозом и гипертонической болезнью. Российский медицинский журнал. 2011;29:1802-8.Polishchuk LS. Features of management of patients with combined pathology — osteoarthritis and hypertension. Russian Medical Journal. 2011;29:1802-8. (In Russ.)Xie Y, Zhou W, Zhong Z, et al. Metabolic syndrome, hypertension, and hyperglycemia were positively associated with knee osteoarthritis, while dyslipidemia showed no association with knee osteoarthritis. Clin Rheumatol. 2021;40:711-24. doi:10.1007/s10067-020-05216-y.Xie Y, Zhou W, Zhong Z, et al. Metabolic syndrome, hypertension, and hyperglycemia were positively associated with knee osteoarthritis, while dyslipidemia showed no association with knee osteoarthritis. Clin Rheumatol. 2021;40:711-24. doi:10.1007/s10067-020-05216-y.Forman DE, Maurer MS, Boyd C, et al. Multimorbidity in Older Adults with Cardiovascular Disease. J Am Coll Cardiol. 2018; 71(19):2149-61. doi:10.1016/j.jacc.2018.03.022.Forman DE, Maurer MS, Boyd C, et al. Multimorbidity in Older Adults with Cardiovascular Disease. J Am Coll Cardiol. 2018; 71(19):2149-61. doi:10.1016/j.jacc.2018.03.022.Singh G, Miller JD, Lee FH, et al. Pevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination survey. Am J Manag Care. 2002;8(15):383-91.Singh G, Miller JD, Lee FH, et al. Pevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination survey. Am J Manag Care. 2002;8(15):383-91.Harley C, Wagner S. The prevalence of cardiovascular risk factors in patients pre-scribing anti-inflammatory drugs; data from managed care. Clin Ther. 2003;25(1):139-49.Harley C, Wagner S. The prevalence of cardiovascular risk factors in patients pre-scribing anti-inflammatory drugs; data from managed care. Clin Ther. 2003;25(1):139-49.Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgetic dose and risk of incident hypertension in US women. Hypertension. 2005;46(3):500-07.Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgetic dose and risk of incident hypertension in US women. Hypertension. 2005;46(3):500-07.Atiquzzaman M, Karim ME, Kopec J, et al. Role of nonsteroidal anti-inflammatory drugs in the association between osteoarthritis and cardiovascular diseases: a longitudinal study. Arthritis Rheumatol. 2019;71(11):1835-43. doi:10.1002/art.41027.Atiquzzaman M, Karim ME, Kopec J, et al. Role of nonsteroidal anti-inflammatory drugs in the association between osteoarthritis and cardiovascular diseases: a longitudinal study. Arthritis Rheumatol. 2019;71(11):1835-43. doi:10.1002/art.41027.Bally M, Dendukuri N, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ. 2017;9(357):j1909. doi:10.1136/bmj.j1909.Bally M, Dendukuri N, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ. 2017;9(357):j1909. doi:10.1136/bmj.j1909.Krotz F, Struthmann L. A Review on the risk of myocardial infarction associated with the NSAID diclofenac. Cardiovasc Hematol Disord Drug Targets. 2010;10(1):53-65. doi:10.2174/187152910790780041.Krotz F, Struthmann L. A Review on the risk of myocardial infarction associated with the NSAID diclofenac. Cardiovasc Hematol Disord Drug Targets. 2010;10(1):53-65. doi:10.2174/187152910790780041.Stewart RAH, Held C, Hadziosmanovic N, et al. Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. J Am Coll Cardiol. 2017;70(14):1689-700. doi:10.1016/j.jacc.2017.08.017.Stewart RAH, Held C, Hadziosmanovic N, et al. Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. J Am Coll Cardiol. 2017;70(14):1689-700. doi:10.1016/j.jacc.2017.08.017.Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal antiinflammatory drugs (NSAIDs) and organ damage: a current perspective. Biochem Pharmacol. 2020;180:114-47. doi:10.1016/j.bcp.2020.114147.Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal antiinflammatory drugs (NSAIDs) and organ damage: a current perspective. Biochem Pharmacol. 2020;180:114-47. doi:10.1016/j.bcp.2020.114147.Ungprasert P, Srivali N, Thongprayoon C. Nonsteroidal antiinflammatory drugs and risk of incident heart failure: a systematic review and meta-analysis of observational studies. Clin Cardiol. 2016;39(2):111-8. doi:10.1002/clc.22502.Ungprasert P, Srivali N, Thongprayoon C. Nonsteroidal antiinflammatory drugs and risk of incident heart failure: a systematic review and meta-analysis of observational studies. Clin Cardiol. 2016;39(2):111-8. doi:10.1002/clc.22502.Alemzadeh-Ansari MJ, Ansari-Ramandi MM, Naderi NJ, et al. Chronic pain in chronic heart failure: a review article. Tehran Heart Cent. 2017;12(2):49-56.Alemzadeh-Ansari MJ, Ansari-Ramandi MM, Naderi NJ, et al. Chronic pain in chronic heart failure: a review article. Tehran Heart Cent. 2017;12(2):49-56.Cooper C, Chapurlat R, Al-Daghri N, et al. Safety of oral non-selective non-steroidal anti-inflammatory drugs in osteoarthritis: what does the literature say? Drugs Aging. 2019; 36 (1):15-24. doi:0.1007/s40266-019-00660-1.Cooper C, Chapurlat R, Al-Daghri N, et al. Safety of oral non-selective non-steroidal anti-inflammatory drugs in osteoarthritis: what does the literature say? Drugs Aging. 2019; 36 (1):15-24. doi:0.1007/s40266-019-00660-1.Majeed MH, Ali AA, Khalil HA. A review of the pharmacological management of chronic pain in patients with heart failure. Innov Clin Neurosci. 2019;16(11):25-7.Majeed MH, Ali AA, Khalil HA. A review of the pharmacological management of chronic pain in patients with heart failure. Innov Clin Neurosci. 2019;16(11):25-7.Ungprasert P, Srivali N, Kittanamongkolchai W. Non-steroidal anti-inflammatory drugs and risk of heart failure exacerbation: a systematic review and meta-analysis. Eur J Intern Med. 2015;26(9):685-90. doi:10.1016/j.ejim.2015.09.012.Ungprasert P, Srivali N, Kittanamongkolchai W. Non-steroidal anti-inflammatory drugs and risk of heart failure exacerbation: a systematic review and meta-analysis. Eur J Intern Med. 2015;26(9):685-90. doi:10.1016/j.ejim.2015.09.012.Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. и др. Клинические рекомендации "Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике". Современная ревматология. 2015;(1):4-23.Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical recommendations "Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice". Modern rheumatology. 2015;(1):4-23. (In Russ.)Hu Y, Yelehe-Okouma M, Ea HK, et al. Galectin-3: a key player in arthritis. Joint Bone Spine. 2017;84(1):15-20. doi:10.1016/j.jbspin.2016.02.029.Hu Y, Yelehe-Okouma M, Ea HK, et al. Galectin-3: a key player in arthritis. Joint Bone Spine. 2017;84(1):15-20. doi:10.1016/j.jbspin.2016.02.029.Gehlken C, Suthahar N, Meijers WC, de Boer RA. Galectin-3 in heart failure: an update of the last 3 years. Heart Fail Clin. 2018;14(1):75-92. doi:10.1016/j.hfc.2017.08.009.Gehlken C, Suthahar N, Meijers WC, de Boer RA. Galectin-3 in heart failure: an update of the last 3 years. Heart Fail Clin. 2018;14(1):75-92. doi:10.1016/j.hfc.2017.08.009.Zhong X, Qian X, Chen G, et al. The role of galectin-3 in heart failure and cardiovascular disease. Clin Exp Pharmacol Physiol. 2019;46(3):197-203. doi:10.1111/1440-1681.13048.Zhong X, Qian X, Chen G, et al. The role of galectin-3 in heart failure and cardiovascular disease. Clin Exp Pharmacol Physiol. 2019;46(3):197-203. doi:10.1111/1440-1681.13048.Wu C, Lv Z, Li X, et al. Galectin-3 in predicting mortality of heart failure: a systematic review and meta-analysis. Heart Surg Forum. 2021;24(2):327-32. doi:10.1532/hsf.3547.Wu C, Lv Z, Li X, et al. Galectin-3 in predicting mortality of heart failure: a systematic review and meta-analysis. Heart Surg Forum. 2021;24(2):327-32. doi:10.1532/hsf.3547.de Lange-Brokaar BJ, Ioan-Facsinay A, van Osch GJ, et al. Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review. Osteoarthr Cartil. 2012;20(12):1484-99.de Lange-Brokaar BJ, Ioan-Facsinay A, van Osch GJ, et al. Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review. Osteoarthr Cartil. 2012;20(12):1484-99.Chou WC, Tsai KL, Hsieh PL et al. Galectin-3 facilitates inflammation and apoptosis in chondrocytes through upregulation of the TLR-4-mediated oxidative stress pathway in TC28a2 human chondrocyte cells. Environ Toxicol. 2022;37(3):478-488. doi:10.1002/tox.23414.Chou WC, Tsai KL, Hsieh PL et al. Galectin-3 facilitates inflammation and apoptosis in chondrocytes through upregulation of the TLR-4-mediated oxidative stress pathway in TC28a2 human chondrocyte cells. Environ Toxicol. 2022;37(3):478-488. doi:10.1002/tox.23414.

The authors declare that there are no conflicts of interest present.